 |
Scopolamine receptors |
|
Situation: Margaret, age 68, was brought to the emergency department of a large regional medical center by her sister-in-law who stated, "She does nothing but sit and stare into space. I can't get her to eat or anything!" Upon assessment, it was found that 6 months ago Margaret's husband of 45 years had died of a massive myocardial infarction. They had no children and had been inseparable. Since her husband's death, Margaret has visited the cemetery every day, changing the flowers often on his grave. She has not removed any of his clothes from the closet or chest of drawers. His shaving materials still occupy the same space in the bathroom. Over the months, Margaret has become more and more socially isolated. She refuses invitations from friends, preferring instead to make her daily trips to the cemetery. She has lost 15 pounds and her sister-in-law reports that there is very little food in the house. Today she said to her sister-in-law, "I don't really want to live anymore. My life is nothing without Frank." Her sister-in-law became frightened and, with forceful persuasion, was able to convince Margaret she needed to see a doctor. Margaret is admitted to the psychiatric unit.
Review articles Drugs. 2000 Feb; 59 2 ; : 213-43. Prevention and treatment of postoperative nausea and vomiting. Kovac AL. Department of Anaesthesiology, University of Kansas Medical Center, Kansas City 66160-7415, USA. akovac kumc Pain, nausea and vomiting are frequently listed by patients as their most important perioperative concerns. With the change in emphasis from an inpatient to outpatient hospital and office-based medical surgical environment, there has been increased interest in the 'big little problem' of postoperative nausea and vomiting PONV ; . Currently, the overall incidence of PONV is estimated to be 25 30%, with severe, intractable PONV estimated to occur in approximately 0.18% of all patients undergoing surgery. PONV can lead to delayed postanaesthesia care unit PACU ; recovery room discharge and unanticipated hospital admission, thereby increasing medical costs. The aetiology and consequences of PONV are complex and multifactorial, with patient-, medical- and surgery-related factors. A thorough understanding of these factors, as well as the neuropharmacology of multiple emetic receptors [dopaminergic, muscarinic, cholinergic, opioid, histamine, serotonin 5hydroxy-tryptamine; 5-HT ; ] and physiology [cranial nerves VIII acoustic-vestibular ; , IX glossopharyngeal ; and X vagus ; , gastrointestinal reflex] relating to PONV are necessary to most effectively manage PONV. Commonly used older, traditional antiemetics for PONV include the anticholinergics scopolamine ; , phenothiazines promethazine ; , antihistamines diphenhydramine ; , butyrophenones droperidol ; and benzamides metoclopramide ; . These antiemetics have adverse effects such as dry mouth, sedation, hypotension, extrapyramidal symptoms, dystonic effects and restlessness. The newest class of antiemetics used for the prevention and treatment of PONV are the serotonin receptor antagonists ondansetron, granisetron, tropisetron, dolasetron ; . These antiemetics do not have the adverse effects of the older, traditional antiemetics. Headache and dizziness are the main adverse effects of the serotonin receptor antagonists in the dosages used for PONV. The serotonin receptor antagonists have improved antiemetic effectiveness but are not as completely efficacious for PONV as they are for chemotherapy-induced nausea and vomiting. Older, traditional antiemetics such as droperidol ; compare favourably with the serotonin receptor antagonists regarding efficacy for PONV prevention. Combination antiemetic therapy improves efficacy for PONV prevention and treatment. In the difficult-to-treat PONV patient as in the chemotherapy patient ; , suppression of numerous emetogenic peripheral stimuli and central neuroemetic receptors may be necessary. This multimodal PONV management approach includes use of: i ; multiple different antiemetic medications double or triple combination antiemetic therapy acting at different neuroreceptor sites ii ; less emetogenic anaesthesia techniques; iii ; adequate intravenous hydration; and iv ; adequate pain control. Eur J Anaesthesiol. 1998 Sep; 15 5 ; : 595-9. The impact of audit in a district general hospital on post-operative nausea and vomiting after major gynaecological surgery. Hadji F, Eastwood D, Fear S, Corfield HJ. Arrowe Park Hospital, Upton, Wirral, UK. An audit of post-operative nausea and vomiting PONV ; was undertaken in 935 female patients who used morphine patientcontrolled analgesia PCA ; for pain relief after major gynaecological operations in a district general hospital. We investigated retrospectively five different antiemetic policies and a reference group without policy from January 1993 to July 1995. The department's computerized audit system was used to analyse the observations. At the beginning of the audit, the incidence of nausea and vomiting was as high as 71.5%. But as a consequence of this audit, a departmental policy was adopted 3 years later, which had an incidence of PONV of only 51.7%. During this time the compliance with antiemetic protocols increased from 41% to 76%. There was significantly less PONV if an antiemetic protocol was followed P 0.002 ; . This emphasizes the importance of corporate involvement in the development, formulation and evaluation of departmental protocols if compliance is to be high. We conclude that audit as a corporate effort improves the acceptance of departmental protocols. This reduces PONV significantly irrespective of the type of antiemetic drug used. Eur J Cancer. 1994; 30A 9 ; : 1223-7. Comment in: Eur J Cancer. 1994; 30A 9 ; : 1217. The roles of patient and observer assessments in anti-emetic trials. Olver IN, Matthews JP, Bishop JF, Smith RA. Medical Oncology Department, Royal Adelaide Hospital, Australia. The endpoints assessed by both patients and nurses were compared in three anti-emetic studies. In a parallel subjects study, there was no significant difference between the patients' and nurses' assessment of the number of vomiting episodes, but the duration of vomiting, the severity and duration of nausea, and the side-effects of the anti-emetic were given higher scores by the nurses. In two cross-over studies, the patients recorded more vomiting episodes than the nurses, while the nurses recorded more anxiety and sedation than the patients. This resulted in the patients detecting a difference between the side-effects of the anti-emetics being compared that was not apparent from the nurses' forms. Many of the differences reflect differences in the timing and frequency of data collection. Nurses collected data regularly during the assessment period whereas patients reported their experiences only at the completion of 24 h. Both assessments provide useful perspectives on the study outcomes.
Transdermal scopolamine withdrawal syndrome
DISCLOSURE: William Stringer, None. THE VALUE OF CARDIO-PULMONARY EXERCISE TESTING CPET ; IN THE DETECTION OF CARDIAC DISEASE IN RESPIRATORY IMPAIRED RI ; PATIENTS Bohdan M. Pichurko, FCCP MD * J. Trosell RRT D. Luneack RRT C. Rubner RRT A. Pichurko Providence Hospital and Medical Centers, Southfield and Novi, MI PURPOSE: Cardiovascular disease CVD ; in respiratory impaired patients is a likely co-morbidity since key risk factors e.g. tobacco use, age ; are shared. As symptoms of dyspnea and chest tightness are non-specific, underlying CVD may too long remain undiagnosed; to the patient's detriment. To determine the diagnostic value of CPET alone and as an addition to conventional cardiac exercise testing in detecting CVD in RI pts, we performed the following experiment. METHODS: 92 subjects, 50M, 42F ; were evaluated for persistent dyspnea by CPET utilizing a stationary bicycle and watt-ramp protocol. Each had a known respiratory disorder COPD, asthma, sarcoid, RADS ; under treatment. 68 of these were also cardiac stress tested over the same interval; with 56 patients considered "low-risk for ischemia". CPET analysis was performed without knowledge of cardiac test results. RESULTS: 81 subjects exhibited a reduced work capacity 85% of the VO2max pred. ; with 65 80% ; exhibiting a pattern of respiratory limitation Breathing reserve 15%; O2sat 89%; FEV1 15% decline ; at peak exercise. 16 20% ; manifest a CV limitation VO2 AT 40% of VO2max; reduced O2 pulse ; . Of the latter CV-limited group, 10 63% ; tested "low-risk for ischemia". All 16 patients underwent re-evaluation including medication changes and or catheterization. CONCLUSION: Respiratory impaired patients appear to be at risk for undetected concurrent cardiovascular disease. Even when utilized, conventional cardiac testing combining exercise with ultrasound or scintiographic imaging ; may overlook non-ischemic CVD. CPET, a metabolically based assessment of global cardiovascular function oxygen delivery, is sensitive to non-ischemic cardiac dysfunction that may evade conventional cardiac stress testing. CLINICAL IMPLICATIONS: Respiratory impaired patients pose particular challenges to clinical suspicion and diagnosis of concurrent cardiovascular disease by conventional cardiac testing modalities. CVD due to hypertension, valvular dysfunction, and primary myocardial disorders may evade cardiac stress testing that principally targets ischemia. A high index of suspicion for concurrent CVD coupled with selective use of CPET may help detect significant cardiovascular impairment and may lead to improved treatment. DISCLOSURE: Bohdan Pichurko, FCCP, None. GAS EXCHANGE ASSESSMENT AT REST AND DURING EXERCISE IN PATIENTS WITH EISENMENGER SYNDROME Edgar G. Bautista MD * Ma. Luisa M. Guerra MD Tomas Pulido MD ~ Efren Santos MD Silvio A. Namendys MD Jose L. Sandoval MD Gerardo Rojas MD David Mendoza MD Julio Sandoval MD Instituto Nacional de Cardiologia "Ignacio Chavez", Mexico City, Mexico PURPOSE: To assess gas exchange and distribution of ventilation in Eisenmenger syndrome patients at rest and while performing submaximal exercise at an altitude of 2240 mts above sea level. METHODS: 93 patients with Eisenmenger syndrome due to ASD 49p, VSD 27p, PDA 20p; 74 females, 19 males. Age 36 14 20-73 ; yo, height 1.53 0.1 m, weight 59 17 Kg. PAP 98 27 mmHg, PaO2 50 8 mmHg, V-A shunt QsQt% 14.9 5, Hb gr dl 17.7 4.2. Gas exchange GE ; was assessed in 70 p room air ra ; , FiO2 1 100% ; and at the end of exercise e ; . Independent student t test; p 0.05 * was considered as significative when compared to ra values also regression analysis with SPSS 10 was applied to data. RESULTS: Spirometry; FEV1 mls. 1877 646; FEV1% 70 18, FEVI FVC% 78 14, FEF% 56 30. GE is presented in table 1. A trend to.
Scopolamine zombie drug
Of hydroxylase activities; 0.03 picokatal in Atropa belladonna lane I ; , 0 picokatal in Brassica campstris lane 2 ; , 0.18 picokatal in Duboisia leichhardlii lane 9 ; . 0.03 picokatal in Hyoscyamus alhus lane 4 ; . 0.02 picokatal in Hyoscyamus 5 gyorffi lane . ; , 0.Ofi picokatal in Hyoscyamus muticus lane fi ; , 0.26 picokatal in H. niger lane 7 ; . and 0 picokatal in Nicotiana tabacum lane 8 ; . The antihodv mAh5 recognized bands of M, 38, 000-40, 000 in cell extracts from all scopolamine-producing root cultures lanes 1 , 3. and 4 - 7 ; and the intensities of the bands were well correlated with the hvdroxylase activities in theextracts.Thestrongest signal was obtained inH. niger, whereas no signals were detected in nonscopolamine-producing cultures of H . camprstris and N . a bacum lanes 2 and 8 ; .The other three antihodies reacted also strongly with the 38-kDa hand of H. nigcr lanr 7 , Fig. 3 ; . The purified HfiH of H. niger Yamada rt 01. 1990 ; also had the same M , of 38.000. There were differences, however, in the specificities of the antihodies. The antihodv mAh55 appeared to recognize almost exclusively the : 18-kI ; a protein of H. niger lane 7, Fig. 3 ; , and mAh94 was specific to Hyoscyamus species lanes 4 " ; , whereas mAhfi7 also recognized a 39-kDa protein of Duboisia lane * ?I. Immunoaffinity Purification--Purified mAh5 antihodv was covalently attached to Sepharose C L 4 resin hv cyanogen bromideactivation. A partially purified H6H preparation from cultured H. niger roots was applied totheantihodv affinity column. Nonspecifically hound protein was washed from the column with a phosphate huffer and specific elution of HfiH was accomplished with 10 mM horate huffer, pH 10.5. The eluted enzymeof 38 kDa appeared to he nearlv homogeHO neous, as judged hv SDS-PAGE and silver staining Fig. 4; .' Miniprint ; . This purified HfiH protein was recognized hv all 60-hydroxy- \ hyoscyamine the four monoclonal antibodies on Western hlots data not N-Me .OR shown ; . Enzyme activity was not detected in the unhound 0 fraction, hut 5-1006 of the applied activitv was recovered in hyoscyamine q&H scopolamine the hound fraction under the elution conditions used. T-ypiH cally HfiH was purified to near homogeneity hv precipitation R -COd-Ph with ammonium sulfate, followed hy chromatography on the kn, on 6, mAh5 affinitv column. hyoscyamine s ; -tropylAbout 220 p g of purified H6H was ohtained after starting Frc. 1. Biosynthetic pathway from hyoscyamine to scopolwith 750 g of cultured roots 1.3 g total protein ; . Thespecific amine. Thepathway hywhich6, 7-dehydrohyoscvamine, a non- activity of the purified enzvme was 930 picokatals mg protein. natural alkaloid, is converted to scopolamine is also shown. H6H catalyzes hot h the hydroxylation of hyoscyamine and the epoxidat ion Because IgM antihodies are not suitahle for affinitv chromatography Arvieux and Williams, 1988 ; . similarimmuof 6, 7-dehydrohyoscyamine. noaffinity resin wasprepared onlywith the other IgG antihodv mAhfi7 as the coupling antihodv. Enzymaticallv active HfiH that had heen partiallv purified hy precipitation with column was first -43 denatured hy treatment with SDS and then loaded on the the mAbfi7 column after removal of excess SDS ; , denatured - 50 5 HfiH protein was specifically retained on the column.Borate huffer of p H 10.5 eluted a homogeneous although enzvmatically inactive ; HfiH protein which was recognized hv all four 55 monoclonal antibodies on Western hlot data not shown ; . 87 Tissue- and Cd-specific Imxdizathn-The relative ahundance of HBH protein invarious tissues of H. niger was 94 determined hv immunohlotting with mAh5 after separation of proteins hv SDS-PAGE Fig. 5 ; . No protein reacting with FIG.3. Immunoblotting of crude extracts from various cultured roots. SI ; S-I'A ; I was performed in a 12.500 polyacrylamide mAh5 was detected in the crude cell extracts from petals, gel with 10 pg o protein applied per lane. The hlots were incuhated calyxes, leaves, stems, cukured cells, or cultured shoots. with monoclonal antihodies mAh5 top gel ; , mAh55, mAh67 rniddlr whereas the HfiH protein of 38 kDa was present in extracts p l s ; , mAh94 hotforngel ; . Only the part of the hlots M , 43.000from plant roots and cultured roots. The amount the HfiH of : 10, 000 ; are shown for mAh55, mAh67, and mAh94. IAne I, A. hrlladonna; lane 2, H . carnpestris; lane 3 , D.lrichhardtii; lane 4, H. alhus; protein in the cultured roots was considerahlv higher than lane Fi, H. g-yorfii; lane 6, H. muticus; lane 7, H . nigrc lane 8, N . that in the mature plantroots. Similar immunohlotting analyses of various H. niger tissues using the other antihodies tahacum.
Treatment for scopolamine poisoning
The anticholinergics antispasmodics are available only with your doctor's prescription in the following dosage forms: oral anisotropine tablets ; atropine tablets ; soluble tablets ; belladonna tincture ; clidinium capsules ; dicyclomine capsules and canada ; syrup and canada ; tablets and canada ; glycopyrrolate tablets and canada ; homatropine tablets ; hyoscyamine extended-release capsules ; extended-release tablets ; elixir ; oral solution and canada ; tablets and canada ; mepenzolate tablets ; methantheline tablets ; methscopolamine pirenzepine tablets canada ; propantheline tablets and canada ; scopolamine tablets canada ; parenteral atropine injection and canada ; dicyclomine injection ; glycopyrrolate injection and canada ; hyoscyamine injection ; scopolamine injection and canada ; rectal scopolamine suppositories canada ; transdermal scopolamine transdermal disk and canada ; brand names some commonly used brand names are: in the anaspaz 8 a-spas s l 8 banthine 10 bentyl 5 cantil 9 cystospaz 8 cystospaz-m 8 donnamar 8 ed-spaz 8 gastrosed 8 homapin 7 levbid 8 levsin 8 levsinex timecaps 8 levsin sl 8 pro-banthine 13 quarzan 4 robinul 6 robinul forte 6 symax sl 8 transderm-scop 14 in canada bentylol 5 buscopan 14 formulex 5 gastrozepin 12 levsin 8 pro-banthine 13 propanthel 13 robinul 6 robinul forte 6 spasmoban 5 transderm-v 14 other commonly used names are: dicycloverine , glycopyrronium bromide , hyoscine hydrobromide , hyoscine methobromide , methanthelinium , and octatropine note: for quick reference, the following anticholinergics antispasmodics are numbered to match the corresponding brand names.
Hydeltrasol , hydramine , hydramine compound , hydramine cough syrup , hydrate , hydroxyzine , hydroxyzine hydrochloride , hydroxyzine pamoate , hyoscyamine , hyoscyamine extended release , hyosol , hyospaz , hyosyne , hypericum perforatum , hyrexin , hyzine , ib-stat , ilosone , ilotycin gluceptate , imatinib , imipramine , imipramine pamoate , imodium , imodium a-d , imodium a-d ez chews , imodium a-d new formula , imotil , indinavir , inh , invega , invirase , isoflurophate ophthalmic , isoniazid , isoptin , isoptin , isoptin sr , isopto carbachol , isopto carpine , itraconazole , j-tan , j-tan pd , kao-paverin , kaopectate caplet , kemadrin , ketek , ketek pak , ketoconazole , key-pred , key-pred sp , l-hyoscyamine , lanreotide , lapatinib , largon , larodopa , levbid , levodopa , levoprome , levsin , levsin sl , levsinex sr , lexiva , liquid pred , lodrane 12 hour , lodrane 24 , lodrane xr , loperamide , loxapine , loxitane , loxitane c , loxitane im , ludiomil , luminal , luvox , maalox anti-diarrheal , maldemar , maprotiline , marezine , mebaral , meclicot , meclizine , medicort , medidex , medidex la , medivert , mellaril , mellaril-s , memantine , meni-d , mepenzolate , mephobarbital , mesoridazine , mestinon , mestinon timespan , methdilazine , methotrimeprazine , methscopolamine , meticorten , metro , metronidazole , metronidazole extended release , metryl , mibefradil , miconazole , migranal , mio-rel , miochol , miochol-e , miochol-e system pak , miochol-e steri-tags , miostat , moban , molindone , monistat , my-e , mycelex troche , mycobutin , myolin , mysoline , mytelase chloride , namenda , nasahist b , navane , navelbine , nd-stat , nefazodone , nelfinavir , nembutal , nembutal sodium , neoral , neostigmine , nervine , nevirapine , nifediac cc , nifedical xl , nifedipine , nifedipine extended release , nightime sleepaid , nilotinib , nizoral , nolahist , norflex , norflex injectable , norpace , norpace cr , norpramin , nortriptyline , norvir , norvir soft gelatin , noxafil , nu-med , nulev , nydrazid , nytol caplet , nytol maximum strength , octreotide , ocu-carpine , ocusert , olanzapine , optimine , orap , orapred , orapred odt , orasone , orfro , ormazine , orphenadrine , orphenadrine extended release , orphenate , oxcarbazepine , oxybutynin , oxybutynin extended release , oxytrol , p-tann , p-tex , pacerone , palgic , paliperidone , pamelor , pamine , pamine forte , pardryl , parlodel , pbz , pbz-sr , pce dispertab , pediapred , pediatan , pediatex , pediatex 12 , pediox , pediox-s , pentazine , pentobarbital , pepto diarrhea control , periactin , permitil , perphenazine , phenadoz , phenazine 50 , phenergan , phenergan fortis , phenindamine , pheniramine , phenobarbital , phenoject-50 , phenylbutazone , phenyltoloxamine , phenytek , phenytoin , phenytoin extended release , phenytoin sodium, prompt , phospholine iodide , physostigmine , physostigmine ophthalmic , pilagan with c cap , pilocar , pilocarpine , pilocarpine nitrate ophthalmic , pilocarpine ophthalmic , pilopine-hs , piloptic-1 , piloptic-1 2 , piloptic-2 , piloptic-3 , piloptic-4 , piloptic-6 , pilostat , pimozide , polaramine , polaramine repetabs , posaconazole , posicor , pramlintide , pred-ject-50 , predacort 50 , predaject-50 , predalone 50 , predate-50 , predcor , predicort rp , predicort-50 , prednicen-m , prednicot , prednisolone , prednisolone acetate , prednisolone sodium phosphate , prednisolone tebutate , prednisone , prelone , prezista , pri-cortin 50 , priftin , primethasone , primidone , pro-banthine , pro-med , procainamide , procainamide 12 hour extended release , procainamide extended release , procan sr , procanbid , procardia , procardia xl , prochlorperazine , prochlorperazine extended release , procot , procyclidine , proleukin , prolixin , prolixin decanoate , prolixin enanthate , promacot , promazine , promethazine , promethegan , pronestyl , pronestyl-sr , prop-a-tane , propantheline , propiomazine , prorex , prostigmin , prostigmin bromide , protostat , protriptyline , prudoxin , pyridostigmine , pyridostigmine extended release , pyrilamine , pyrilamine extended release , pyrlex , q-dryl , q-dryl a f , qdall ar , quarzan , quenalin , quetiapine , quetiapine extended release , quin-g , quin-release , quinaglute dura-tabs , quinidex extentabs , quinidine , quinidine extended release , quinora , razadyne , razadyne er , regonol , regurin , reminyl , rescriptor , reversol , reyataz , rezine , rezulin , ridramin , rifabutin , rifadin , rifadin iv , rifampin , rifapentine , rimactane , risperdal , risperdal consta , risperdal m-tab , risperidone , ritonavir , rivastigmine , robimycin , robinul , robinul forte , rohist , ru-vert-m , sal-tropine , salagen , sanctura , sandimmune , sandostatin , sandostatin lar depot , saquinavir , saquinavir mesylate , scopace , scopolamine , scopolamine topical , scot-tussin allergy relief formula , secobarbital , seconal sodium , serentil , seroquel , seroquel xr , serzone , siladryl , siladryl das , siladyl sa , silphen cough , siltane , simply sleep , sinequan , sleep tab ii , sleep tabs , sleep-ettes , sleep-eze-3 , sleepinal , solfoton , solurex , solurex la , somatuline depot , sominex , sominex maximum strength caplet , somnicaps , sparine , spasdel , sporanox , sprycel , st and secobarbital.
Scopolamine hbr patch
Web site ; specifically, antivert, bonine, meclizine, dramamine, scopolamine seem to be of little use.
1 Jones RE, Deutsch S, TurndorfH. Effects of atropine on cardiac rhythm in conscious and anesthetised man. Anesthesiology 1961; 22: 67-73. Farman JV. Circulatory effects of atropine during halothane anaesthesia. Br J Anaesth 1967; 39: 226-35. EikardB, Andersen JR. Arrhythmias during halothane anaesthesia.Q: The influence of atropine. Ada Anaesthesiol Scand 1977; 21: 245-51. EgerEI. Atropine, scopolamine and related compounds. Anesthesiology 1962; 23: 365-83. MirakhurRK, Jones CJ, Atropine and glycopyrrolate: Changes in cardiac rate and rhythm in conscious and anaesthetised children. Anaesth Intensive Care 1982; 10: 328-32. Samra SK, Cohen PJ. Modification of chronotropic response to anticholinergics by halogenated anaesthetics in children. Can Anaesth Soc J 1980; 27: 540-5. Yamaguchi H, Dohi S, Sato S, Naito H. Heart rate response to atropine in humans anaesthetised with five and senna.
A l t sinqe Hitler absorbed the C g e the postal Uup still persists. T h e Issued by t h Cenho 5!ovak Hepublig appeared just two days before the eraek-up. I t b o haleru a l u Hginaliy If s u 1935, in t h e 50-haJerii v a l u first t h i officials d i d upon t a k over the postal system in B o overp r i n all s t a circulation. S i n reg u l a tituted, S l o v fared differently. When Hitler entered Bohemia, Slovakia d e c the Cseeho-Slovak Republic. F o r one d a y dependenee by oveTprlntlng' 2i? Geecho-Slovak issues w i t the w o r WW, " m e a Slovakia 1939, O n t h self a G e parently It still retains nominal c o n Its p o s t'lftJltCH O F T AIR. p r i faghifiR 7 thfe p a p isffue M5d a l s will be u n ka, a Ssovak h e r Sei M o r recently It h a enee C o m Publication fsr r e g .Hl!n N e w wlll' b e " with a Slovak overprintP o w e will b e g Church of C h Scienflflt, Red Fratice cams through la tweek.
| Atropine and scopolamine to quit smokingDrug Antihistamines Diphenhydramine Cyclizine Meclizine Anticholinergics Scopolamine 250800 g PO prior to emeticproducing activity or TDP q 72 hours or 0.820 mg as a CSI q 24 hours 0.1250.250 mg PO or SL q hours prn or 0.250.5 mg SQ q 4 hours prn or 12 mg as a CSI q 24 hours Promethazine Droperidol Substituted benzamide Metoclopramide 520 mg PO, IM * , IV, or SQ q 6 hours prn or 2080 mg as a CSI q 24 hours 25 mg PO, IV, or IM * q 4 hours prn 50 mg PO or IM * q hours prn or 50100 mg as a CSI q 24 hours 2550 mg PO q 46 hours prn Starting Dosage Drug Dopamine antagonists Haloperidol 0.52 mg PO, IM * , IV, or SQ q 46 hours prn or 515 mg as a CSI q 24 hours 520 mg PO, IM * , or IV q hours prn or 25 mg PR q 4 hours prn 25 mg PO or PR q hours prn or 12.525 mg IV q 46 hours prn 2.55 mg IV q 46 hours prn Starting Dosage and septra.
Anticholinergics: scopolamine and atropine are surgical drying agents.
Scopolamine powder
Massive invasion of the bone marrow. A necropsic study of nine cases. Cancer 1983: 52: 1927-32. Lukes JR. Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966; 26: 1063-81. Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989: 7: 1630-6. Sucliffe SB, Lister TA. Cotswolds modifications of the Ann Arbor staging system for Hodgkin's disease. J Clin Oncol 1990; 8: 1598. De Vita VT, Serpick A. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Proc Assoc Cancer Res 1967; 8: 13 Abstr ; . Bonadonna G, Zucali R, Monfardini S et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252-9. Kaplan HS, Rosenberg SA. Extended field radical radiotherapy in advanced Hodgkin's disease. Cancer Res 1966; 26: 1268-76. Aragon de la Cruz G, Cardenes H, Otero J et al. Individual risk of abdominal disease in patients with stages I and II supradiaphragmatic Hodgkin's disease. A rule index based on 341 laparotomized patients. Cancer 1989; 63 9 ; : 1799-803. Urba WJ, Longo D. Hodgkin's disease. N Engl J Med 1992; 10: 678-87. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Stat Assoc 1958; 59: 1107-11. Armitage P, Berry G. Statistical Methods in Medical Research. Oxford. Blackwell Scientific 1987. Morant R, Schonenberger I, Schmid U. Are autopsies still useful in oncology? Proc Soc Clin Oncol 1996; 15: 194. Goldman L, Sayson R, Robbins S et al. The value of the autopsy in three medical eras. N Engl J Med 1983; 308: 1000-5. Kirch W, Schafii C. Misdiagnosis at a university hospital in four medical eras. Medicine Baltimore ; 1996; 75 I ; : 29-40. Vaughan Hudson B, Vaugan Hudson G, Linch DC et al. Late mortality in young patients cured of Hodgkin's disease. Ann Oncol 1994; 5 Suppl 2 ; : S65-6. Henry-Amar M, Joly F. Late complications after Hodgkin's disease. Ann Oncol 1996; 7 Suppl 4 ; : SI 15-26. Burton EC, Troxclair DA, Newman WP III. Autopsy diagnoses of malignant neoplasms. How often are clinical diagnoses incorrect? JAMA 1998; 280: 1245-8. Cocchi A, Vecchio FM, Pahor M et al. Autopsy rate in younger and older hospitalized patients. Eur J Epidemiol 1986; 2: 151-7. Nordentoff AM, Pedersen-Bjergaard J, Brincker H et al. Hodgkin's disease in Denmark. A national clinical study by the Danish Hodgkin's study group. Scand J Haematol 1980; 24: 321-34. Wedelin C, Bjorkholm M, Biberfeld P et al. Prognostic factors in Hodgkin's disease with special reference to age. Cancer 1984; 53: 1202-8. Nieman RS, Rosen PJ, Lukes RJ. Lymphocyte-depletion Hodgkin's disease. N Engl J Med 1973; 288: 751-5. Krikorian JG, Portlock CS, Mauch PM. Hodgkin's disease presenting below the diaphragm: A review. J Clin Oncol 1986: 4 10 ; : 1551-62. Villamor N, Reverter JC, Marti JM et al. Clinical features and response to treatment of infradiaphragmatic Hodgkin's disease. Eur J Haematol 1991; 46: 38-41. Brincker H. Sarcoid reactions in malignant tumors. Cancer Treat Rev 1986; 13: 147-56. Larson EB, Featherstone HJ, Petersdorf RG. Fever of undetermined origin: Diagnosis and follow-up of 105 cases. Medicine 1982; 61 5 ; : 269-92. Petersdorf RG. Fever of unknown origin. Arch Intern Med 1992; 152: 21-2 and serostim.
Order Scopolamine
| HE PRODUCT of the BCL-2 genesuppressesprogrammed death cell apoptosis ; .'-3 Thus, enforced BCL-2 expression delays apoptosisof celllinesdeprived of essential survival factors: and prolongs the life-span of lymphocytes in BCL-2 transgenic mice."' Overexpression of BCL-2 may also confer resistance to cytotoxic agents. For example, enforcedBCL-2 expression increases the resistance of thymocytes to glucocorticoids and r a d nand of leu, ~ kemiccelllines to avariety of anticancer drugs.'. * Conversely, cytokine- orantisense-mediated reduction of BCL-2 expression enhances sensitivity to several cytotoxic drugs.'.'" These findings indicate that BCL-2 could function a multias drug resistance molecule and that its measurement could be of prognostic value. This hypothesis gains support from the association of higher BCL-2 levels with poorer responses to chemotherapy in acute myeloid leukemia AML ; , ".' * with unfavorablehistology and N-MYC amplification in neuroblastoma, I3with androgen independency in prostate carciFrom the Departments of Hematology-Oncology, Pharmaceutical Sciences, and Pathology and Laboratoty Medicine, St Jude Chilf f dren's Research Hospital; University o Tennessee, College o Medicine, Memphis; and Clinica Pediatrica Universita, Pavia. Italy. Submitted June 26, 1995; accepted September 12, 1995. Supported by Grants No. ROI-CA58297, P3O-CA21765. and POICA20180 from the National Cancer Institute; and by the American Lebanese Syrian Associated Charities ALSAC ; , St Jude Children's Research Hospital. Address reprint requests to Dario Campana, MD, PhD, DepartSt Jude Children'.r Research Hospiment of Hematolog~l-Oncol~~gy, tal, 332 North Lauderdale, Memphis TN 38101. The publication costsof this article were defrayed part by page in marked charge payment. This article must therefore be hereby "advertisement" i n accordance with 18 U.S.C. section 1734 solely to indicate this fuct. 0 I996 by The American Society of Hematology. 0006-4971 96 8703-0038.00 0.
Use phenylephrine scopolamine with caution and sevelamer.
Middot; store atropine hyoscyamine pb scopolamine at room temperature away from moisture and heat.
Scopolamine is an anticholinergic medicine and sirolimus.
45. Sjogren K, Sheng M, Moverare S, Liu JL, Wallenius K, Tornell J, Isaksson O, Jansson JO, Mohan S, Ohlsson C 2002 Effects of liver-derived insulin-like growth factor I on bone metabolism in mice. J Bone Miner Res 17: 19771987 46. Baxter RC, Meka S, Firth SM 2002 Molecular distribution of IGF binding protein-5 in human serum. J Clin Endocrinol Metab 87: 271276 47. Butt AJ, Dickson KA, McDougall F, Baxter RC 2003 Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem 278: 29676 29685 Ernst M, Heath JK, Rodan GA 1989 Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. Endocrinology 125: 825 833 Gori F, Hofbauer LC, Conover CA, Khosla S 1999 Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinology 140: 5579 5586 Fournier B, Gutzwiller S, Dittmar T, Matthias G, Steenbergh P, Matthias P 2001 Estrogen receptor ER ; - , but not ER- , mediates regulation of the insulinlike growth factor I gene by antiestrogens. J Biol Chem 276: 35444 35449 Liu JL, Yakar S, LeRoith D 2000 Mice deficient in liver production of insulinlike growth factor I display sexual dimorphism in growth hormone-stimulated postnatal growth. Endocrinology 141: 4436 4441 Thoren M, Hilding A, Brismar T, Magnusson P, Degerblad M, Larsson L, Saaf M, Baylink DJ, Mohan S 1998 Serum levels of insulin-like growth factor binding proteins IGFBP ; -4 and -5 correlate with bone mineral density in growth hormone GH ; -deficient adults and increase with GH replacement therapy. J Bone Miner Res 13: 891 899 Adesanya OO, Zhou J, Bondy CA 1996 Cellular localization and sex steroid and scopolamine.
Butyl scopolamine bromide
Area was swollen, firm and tender with massive adenopathy measuring 12 centimeters cm ; by 8 cm; no discharge or warmth to touch was noted. The left groin area revealed a well-healed inguinal scar consistent with prior surgery and non-tender adenopathy recorded as 4 cm without erythema, warmth, or discharge. Initial laboratory testing included a complete blood count with differential, chemistry panel, coagulation panel, urinalysis, and computerized tomography CT ; scans of the abdomen and pelvis. Blood tests were unremarkable except for mild anemia with hemoglobin of 10.2 grams deciliter g dl ; . The CT scan revealed extensive retroperitoneal, pelvic, and bilateral inguinal adenopathy [figure 1]. Following an initial assessment in the emergency department, this patient was admitted for further work-up and pain control. Differential diagnoses were focused on infectious and malignant etiologies [table 1]. Upon admission, additional laboratory studies were ordered including repeat complete blood count with differential, liver profile, Erythrocyte Sedimentation Rate ESR ; , protein electrophoresis, and serum immunoelectrophoresis to rule out multiple myeloma, given the chronic hip pain. CT scan of the chest showed an enlarged right paratracheal lymph node. Radiographs of right hip revealed mixed sclerotic and lytic lesions of the acetabulum and femur. Bone scan showed increased uptake in right femoral head, trochanter and proximal shaft of femur. The differential diagnosis at this point included lymphoma, multiple myeloma, and HIV adenopathy. Surgical and infectious disease consultations were requested. The infectious disease service noted this patient's immunocompromised status and the possibility of an ineffective febrile response. Accordingly, the possibility of an infectious etiology was expanded to include infectious adenitis, disseminated mycobacterium avium intercellulare MAC ; infection, disseminated tuberculosis, cryptococcosis, histoplasmosis and rhodococcus equi Nocardia restricta ; . Histoplasmosis was unlikely as there was no reported travel to histoplasmosis endemic regions. Additional studies were performed: hepatitis profile to rule out hepatitis infection and a viral panel Human Herpes Virus [HHV]8, Human T-cell Lymphotrophic Virus [HTLV]-1 & HTLV11, and Epstein Barr Virus [HBV] ; , since viral infections have been associated with certain malignancies in HIVpositive patients. Open biopsy and fine needle re-biopsy of the right inguinal lymph nodes were completed by the surgical and skelaxin
Scopolamine 0.25% od b i d
Seizure nursing intervention, medrol herniated disc, congestive epididymitis vasectomy, rna electrophoresis 18s 28s and trisomy 22. Treatment of hemodialysis catheter infections, cardiac septum defect, meperidine lethal dose and euphoria 921 or syndrome x 209.
Scopolamine patches dose
Scpolamine, scoploamine, sckpolamine, scopolamins, scipolamine, scopolaminee, scop9lamine, scopolmine, scopolamiine, scopolxmine, copolamine, scopolsmine, scopllamine, zcopolamine, scopolamime, ecopolamine, sc0polamine, scopolqmine, scopolamije, scopolaminne.
Scopolamine medicine
Transdermal scopolamine withdrawal syndrome, scopolamine zombie drug, treatment for scopolamine poisoning, scopolamine sea sickness patch and scopolamine hbr patch. Atropine and scopolamine to quit smoking, scopolamine powder, order scopolamine and butyl scopolamine bromide or scopolamine 0.25% od b i d.
|